Key Insights from J.P. Morgan’s 2024 Annual Healthcare Conference
Held in San Francisco in January, the J.P. Morgan’s Annual Healthcare Conference assembled industry insiders, global leaders, innovative tech creators, and investors. This annual event offered significant insight into the present industry landscape, providing valuable perspectives to shape the future ahead. Here we share our understanding of the current challenges and opportunities that are influencing the healthcare investment landscape.
Key Insights
Early-stage MedTech CEOs are navigating a landscape of uncertainty, seeking feedback from thought leaders to understand the fundraising climate for 2024.
Regulatory Challenges and Funding Realities
-
-Essential regulatory milestones for complex moderate to high-risk technologies will encompass obtaining FDA Pre-Submission feedback and securing FDA marketing clearance, granting, or approval.
-Close monitoring of the pending LDT regulation is essential for informed decision-making.
-Robust reimbursement strategies are identified as crucial for successful Series A raises and beyond.
-For Seed stage companies raising a Series A Flat or modest up rounds will persist in 2024
-Cash conservation and path to mid-seven figure ARR for Series A and B stage companies will be a must
Valuations will Return to Historic Norms
-
-Seed stage investments have pre-money valuations ranging between 7-12 million.
-Companies are showing a readiness to give up a larger share of equity during A and B rounds
-There is an acceptance of flat rounds in exchange for a more certain fundraising climate in 2025.
Regulatory Intelligence
-
-LDT Regulations: Companies are closely monitoring pending regulations to adapt to the evolving landscape. MIP provides actionable insights for “Understanding the LDT Proposed Rule”.
-Digital Health Guidance: Insights are sought to navigate the dynamic digital health space. MIP provides insight in how to “Future Proof Your Digital Health Company”
-Breakthrough Designation Guidance: Understanding and leveraging breakthrough designations for innovative products.
Conclusion
As industry players navigate fundraising uncertainties, adapt valuations, and stay abreast of regulatory developments, the path forward becomes clearer. The commitment to innovation, coupled with strategic decision-making, will undoubtedly steer the healthcare industry towards a future defined by groundbreaking advancements and sustainable growth. These insights paint a complex but intriguing picture of the industry as we navigate the opportunities and challenges that 2024 holds. Stay tuned for more updates and discussions.
About Medtech Impact Partners | Talk to the FDA before you talk to the FDA™
MedTech Impact Partners is a leader in regulatory strategy and support. Built on decades of government and private sector experience, our services position clients to get innovative health technologies to market faster.
Our team of consultants guide MedTech companies over regulatory hurdles at the FDA, helping them deliver on key milestones and protect their bottom line. MIP’s customized approach and suite of services focus on developing sound regulatory strategy, diligent review, and managing risks for clients.
Need regulatory support? Our team is scheduling discovery meetings to learn more about your organization and goals. If you’re interested in learning more, please contact us.